New drug combo aims to shrink pancreatic tumors before surgery
NCT ID NCT05908747
First seen Feb 15, 2026 · Last updated May 17, 2026 · Updated 14 times
Summary
This study tests whether adding surufatinib to standard chemotherapy can help shrink pancreatic tumors enough for successful surgery. It includes 29 adults with locally advanced or borderline resectable pancreatic cancer who have not had prior treatment. The main goal is to see how many patients have a complete tumor removal with clear margins.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.